Improving the pharmacokinetic properties of therapeutic antibodies



13 Mars 2017

Partager sur facebook Partager sur twitter Partager sur linkedin Partager sur google+

Fields

Biology / Medical

Sectors

Health

Context

The market of therapeutic monoclonal antibodies (mAbs) is on the rise :

  • An average of 4 new mAbs approved per year.
  • Estimated 70 antibodies on the market in 2020.
  • Worldwide sales should reach 125 Mds$ by 2020. Antibodies currently commercialized are from caucasian allotypes. Modulation of pharmacocinetic properties participates in increasing efficiency of mAbs.

Technology

The technology consists in developing mAbs with a Fc fragment of the Asian allotype. This results in an increased binding to FcRn receptor of endothelial cells compared to caucasian allotype-based mAbs. This receptor modulates the biodistribution and halflife of antibodies. With the Asian allotype, the binding of mAbs to FcRn receptor is increased by 10% and the stability of this binding is improved by about 40%. Consequently therapeutic antibodies developed with Asian allotype should display a longer half-life in both caucasian and Asian patients:
- Caucasian : better affinity for FcRn receptor than endogen antibodies.
-Asian : No unfavorable competition with endogen antibodies for binding FcRn.

Competitive advantage

  • Increased half-life of therapeutic antibodies.
  • Theorically less immunogenic mAbs than artificial Fc mutants that are also developped to improve the pharmacokinetic properties of mAbs.
  • Non extensive modification of mAb production processes.
Download the offer Download the offer

Newsletter